| Biomarker ID | 1720 |
| PMID | 30719174 |
| Year | 2019 |
| Biomarker | FOXM1 (Forkhead Box M1) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathway include: Regulation of PLK1 Activity at G2/M Transition; Cell Cycle, Mitotic; DNA Damage; Cellular senescence (KEGG); Cyclin A/B1 associated events during G2/M transition |
| Experiment | Prostate Cancer Vs Benign prostatic hyperplasia |
| Type of Biomarker | Diagnostic |
| Cohort | Tissues were collected from patients with low (n=17), intermediate- (n=36), and high-risk (n=29) disease and from patients with CRPC (n=2) and from patients with BPH (n=28) |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.851 (95% CI: 0.783- 0.920) |
| Accuracy | NA |
| Level Of Significance | p<0.001 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |